User:Mr. Ibrahem/Procyclidine
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605037 |
| Routes of administration | By mouth, im, iv |
| Drug class | Anticholinergic[1] |
| Pharmacokinetic data | |
| Protein binding | ~100%-albumin |
| Elimination half-life | ~12 h |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C19H30ClNO |
| Molar mass | 323.90 g·mol−1 |
| (verify) | |
Procyclidine, sold under the brand name Kemadrin among others, is a medication used to treat parkinsonism and extrapyramidal symptoms due to antipsychotics.[1] It improves tremors less than it improves rigidity.[1] It is taken by mouth or by injection into a vein or muscle.[1][2]
Common side effects include dry mouth, blurry vision, nausea, constipation, and lightheadedness.[1] Other side effects may include a fast heart rate, low blood pressure, urinary retention, confusion, and glaucoma.[1] Safety in pregnancy is unclear.[1] It is an anticholinergic.[1]
Procyclidine was approved for medical use in the United States in 1955.[1] It is available as a generic medication.[2] In the United Kingdom 100 tablets of 5 mg costs the NHS about £5 as of 2021.[2] It is no longer commercially available in the United States as of 2008.[3]
References[edit]
- ^ a b c d e f g h i j k "Procyclidine Monograph for Professionals". Drugs.com. Archived from the original on 23 October 2021. Retrieved 29 October 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 432. ISBN 978-0857114105.
- ^ "King discontinues Kemadrin tablets". MPR. 5 June 2008. Archived from the original on 4 December 2020. Retrieved 29 October 2021.